Kymera Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2019 | $17.9M | $17.4M | $532.0K | $1.2M |
| FY2020 | $88.1M | $79.0M | $9.1M | $5.2M |
| FY2021 | $-128.9M | $-130.5M | $1.6M | $25.0M |
| FY2022 | $-153.1M | $-155.9M | $2.8M | $35.5M |
| FY2023 | $-102.8M | $-137.3M | $34.5M | $43.1M |
| FY2024 | $-194.5M | $-207.3M | $12.8M | $55.0M |
| FY2025 | $-232.9M | $-234.3M | $1.4M | $59.9M |